Enicepatide enters phase 3 with a cardiovascular outcomes trial in obesity and CVD
Roche is moving enicepatide into a large phase 3 outcomes study designed to answer a question that sits at the intersection of cardiology and metabolic medicine: can a dual GLP-1/GIP receptor agonist reduce major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease? The trial, named Enith-MACE, is not yet recruiting and is planned as a randomized, double-blind, placebo-controlled study with an estimated 8,200 participants.
The study is built around a population already carrying substantial vascular risk. Adults 18 years and older with a body mass index of at least 25 kg/m2 and stable cardiovascular disease may be eligible, with or without type 2 diabetes. Background therapy for hyperlipidemia and diabetes must already be stable if relevant, and participants with diabetes need an HbA1c of 10% or less at screening. Those criteria point to a cohort that reflects real-world cardiometabolic complexity rather than a narrowly selected obesity sample.
One sentence captures the stakes: this is an event-driven trial, not a weight-loss demonstration.
A composite endpoint built to measure hard cardiovascular outcomes
The primary endpoint is time to first occurrence of any component of 5-point MACE, defined here as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure or urgent heart failure visit, or urgent coronary revascularization. Follow-up for the primary outcome extends from randomization for up to 4.2 years, giving the design enough time to capture relatively infrequent but clinically decisive events. Secondary outcomes expand the lens further with 3-point MACE, 4-point MACE, new-onset type 2 diabetes, all-cause hospitalization, all-cause mortality, cardiovascular death, and adverse events.
The endpoint structure matters because it reflects how a therapy in obesity now has to prove itself in cardiovascular medicine. Weight reduction alone is no longer the bar when a drug class has already demonstrated metabolic activity; the relevant question is whether vascular biology changes enough to alter infarction, stroke, heart failure admissions, and death. Dual incretin agonism offers a plausible mechanism for that effect. By engaging both GLP-1 and GIP pathways, enicepatide is being tested in a therapeutic space where appetite regulation, glycemic improvement, and downstream cardiometabolic remodeling may converge on the arterial wall and the failing heart.
The trial also includes quality-of-life measures through week 48, using multiple domains of the SF-36 v2 acute form, including physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health, and the physical component summary. Those patient-reported outcomes will not replace the cardiovascular endpoints, but they can show whether any benefit is felt in daily function before a hard event endpoint is reached.
Eligibility reflects a high-risk cardiometabolic population
The inclusion criteria point to adults with established, stable cardiovascular disease and excess body weight, with obesity treatment kept in the background rather than layered in through other incretin-based therapies. Participants must not be using GLP-1 receptor agonist-based treatments, which helps keep the effect of enicepatide interpretable. Exclusion criteria remove several groups likely to face safety or confounding problems, including people with type 1 diabetes, recent ketoacidosis or hyperosmolar coma, clinically significant gastric emptying disorders such as severe gastroparesis or gastric outlet obstruction, chronic dialysis, and anyone with a preplanned major medical procedure or obesity surgery at screening.
Those exclusions are clinically sensible. GLP-1–based therapies can slow gastric emptying, and that pharmacology becomes a concern in patients with severe upper gastrointestinal dysmotility. Chronic dialysis and unstable medical conditions would also complicate both safety interpretation and event attribution in a long cardiovascular outcomes trial. The study is set up to test a drug’s preventive potential in a population that can realistically stay on treatment long enough for vascular differences to emerge.
A second sentence lands with equal force: severe gastrointestinal dysfunction has been fenced off before the first dose is given.
Why a dual incretin strategy is being tested for cardiovascular prevention
Enicepatide carries several development codes, including RO7795068, CT-388, and RG6640, and is being studied as a combination product in a parallel-group design. The scientific premise is straightforward even if the biology is not. GLP-1 receptor agonism can reduce appetite, improve glycemia, and lower body weight, while GIP activity may augment metabolic effects and potentially improve tolerability or efficacy depending on the compound’s profile. In a patient with overweight or obesity and existing cardiovascular disease, lowering adiposity can reduce blood pressure load, improve insulin resistance, and lessen inflammatory signaling that contributes to plaque instability and heart failure progression.
That mechanistic logic is why the primary outcome does not stop at myocardial infarction or stroke. Heart failure hospitalization and urgent heart failure visits are embedded in the 5-point MACE definition, acknowledging that obesity-related cardiovascular risk often expresses itself through volume intolerance, myocardial strain, and declining functional reserve, not only through coronary thrombosis. Urgent coronary revascularization is included as well, recognizing the tight link between metabolic risk and progressive atherosclerotic burden.
The trial design also allows for a clinically important subgroup question: whether the therapy prevents progression to new-onset type 2 diabetes in participants who do not yet have established diabetes. If a cardiovascular drug also delays diabetes onset, the downstream effect could be broad, because the two diseases reinforce each other through shared inflammatory, endothelial, and hemodynamic pathways.
The long timeline signals a true outcomes trial, not a short metabolic study
Study start is estimated for January 6, 2027. Primary completion is projected for March 20, 2031, with overall completion expected by April 17, 2031. That timeline is long enough to suggest a serious attempt to quantify cardiovascular benefit in a population whose event rate will depend on baseline risk, treatment adherence, and the consistency of background medical therapy. In a field crowded with short-duration obesity programs, the extended follow-up separates a weight-management study from a prevention trial.
The study is sponsored by Hoffmann-La Roche and listed as a phase 3, interventional trial with randomized allocation and double masking for both participants and investigators. Placebo is volume-matched, which is standard for maintaining blinding in injectable therapies. The study will need that rigor because the outcomes include subjective elements such as urgent heart failure visits and hospitalization patterns, where knowledge of treatment assignment can subtly distort clinical behavior if blinding fails.
The most consequential uncertainty is not whether enicepatide can change laboratory values or body weight. The unanswered question is whether those biologic shifts translate into fewer deaths, fewer infarctions, fewer strokes, and fewer heart failure events in a population already living with cardiovascular disease and excess weight. Until the first participants are enrolled and the event curves begin to separate, the study remains a design built around a powerful hypothesis rather than a clinical result.